AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6196841 — intervention group
Group type: COMPARATOR
Intervention: Methenamine (Hiprex) given daily from the day before the operation for a total of six days
Number of subjects: 42
Study 31600363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus Doxorubicin
Number of subjects: 0
Study 31600363 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 0
Study 30318332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular implantation of 40 × 10^6 autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 43
Study 30318332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mL normal saline)
Number of subjects: 43
Study 28052810 — intervention group
Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 2474
Study 28052810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh inlay
Number of subjects: 2474
Study 28052810 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological graft
Number of subjects: 2474
Study 28052810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh
Number of subjects: 2474
Study 28052810 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft
Number of subjects: 2474
Study 28052810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh kit
Number of subjects: 2474
Study 24503679 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft plus autologous bone marrow concentrate
Number of subjects: 24
Study 24503679 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac crest bone
Number of subjects: 24
Study 22906114 — intervention group
Group type: EXPERIMENTAL
Intervention: Early orthodontic treatment (initial maxillary expansion and subsequent activator therapy)
Number of subjects: 77
Study 22906114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early orthodontic treatment)
Number of subjects: 77
Study 21178929 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week active stretching program
Number of subjects: 18
Study 21178929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 21178929 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stretching program
Number of subjects: 18
Study 16940468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour midafternoon nap (1400-1600) after a night of sleep loss
Number of subjects: 41
Study 15578048 — intervention group
Group type: COMPARATOR
Intervention: Lower levels of beta-carotene in hypertensive participants compared to normotensive participants.
Number of subjects: 415
Study 15578048 — intervention group
Group type: COMPARATOR
Intervention: Higher levels of uric acid in hypertensive participants compared to normotensive participants.
Number of subjects: 415
Study 15578048 — intervention group
Group type: COMPARATOR
Intervention: Higher levels of malondialdehyde (MDA) in hypertensive participants compared to normotensive participants.
Number of subjects: 415
Study 12394122 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine treatment (I-131)
Number of subjects: 71
Study 9920085 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg/week)
Number of subjects: 10
Study 9920085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7755383 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-90 (500-750 mL/day)
Number of subjects: 138
Study 7755383 — intervention group
Group type: COMPARATOR
Intervention: C/MF (Amiparen, 600-800 mL/day)
Number of subjects: 138
Study 2251028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat semielemental diet (60% of fat as medium-chain triglycerides)
Number of subjects: 50
Study 2251028 — intervention group
Group type: COMPARATOR
Intervention: Standard semielemental diet (Pregestimil)
Number of subjects: 50
Study 2251028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (High-fat and Standard)
Number of subjects: 50
Study 6118944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6118944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 6118944 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine and Ranitidine
Number of subjects: 0
Study 30772866 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intranasal tranexamic acid (TXA)
Number of subjects: 450
Study 30772866 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 450
Study 27995674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT), 24 sessions
Number of subjects: 18
Study 27995674 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 18
Study 25661397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive stand-alone working memory training
Number of subjects: 98
Study 25661397 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 98
Study 24727369 — intervention group
Group type: EXPERIMENTAL
Intervention: Online smoking intervention with testimonials
Number of subjects: 1865
Study 24727369 — intervention group
Group type: COMPARATOR
Intervention: Online smoking intervention without testimonials
Number of subjects: 1865
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Ca salts of palm oil fatty acids (DM basis)
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Ca salts of palm oil fatty acids (DM basis)
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.052 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.103 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.155 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion (0.069 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion (0.138 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion (0.207 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding fat
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 18
Study 21178181 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion
Number of subjects: 18
Study 21178181 — intervention group
Group type: COMPARATOR
Intervention: Control (0% added fat)
Number of subjects: 18
Study 18515460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-15 mg)
Number of subjects: 75
Study 18515460 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 75
Study 18515460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 75
Study 18515460 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 75
Study 17709994 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS + CIT (n = 9)
Number of subjects: 19
Study 17709994 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS + CIT (n = 10)
Number of subjects: 19
Study 17709994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rTMS + CIT and Sham rTMS + CIT)
Number of subjects: 19
Study 14986114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1G/2G genotypes in gastric cancer patients
Number of subjects: 215
Study 14986114 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological differentiation in gastric cancer patients
Number of subjects: 215
Study 12397863 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 12
Study 12397863 — intervention group
Group type: EXPERIMENTAL
Intervention: Left dorsolateral pre-frontal cortex (DLPFC) stimulation
Number of subjects: 12
Study 12397863 — intervention group
Group type: EXPERIMENTAL
Intervention: Left DLPFC stimulation in a parallel-groups design
Number of subjects: 12
Study 12397863 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 12
Study 12397863 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 9704771 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (Cytotec)
Number of subjects: 200
Study 9704771 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 200
Study 9704771 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 200
Study 7774313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metaproterenol aerosol pretreatment
Number of subjects: 10
Study 7774313 — intervention group
Group type: COMPARATOR
Intervention: No bronchodilator
Number of subjects: 10
Study 3291110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl aerosol (n = 19)
Number of subjects: 53
Study 3291110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribomunyl aerosol and injections (n = 17)
Number of subjects: 53
Study 3291110 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 53
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2012 RCT preparation costs
Number of subjects: 66
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 RCT preparation costs
Number of subjects: 66
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2012 REC approval time for single centre RCTs
Number of subjects: 66
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 REC approval time for single centre RCTs
Number of subjects: 66
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2012 Swissmedic approval time for any clinical trial
Number of subjects: 66
Study 30633776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 Swissmedic approval time for any clinical trial
Number of subjects: 66
Study 29231500 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture applied to Zhongji (CV 3) and Qugu (CV 2), once a day, 5 times a week for 6 weeks.
Number of subjects: 60
Study 29231500 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules, 0.2 mg, once a day for 6 weeks.
Number of subjects: 60
Study 26619557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine tablets
Number of subjects: 24
Study 23938097 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% price discount on fruit, vegetables, water and diet soft-drinks
Number of subjects: 20
Study 23938097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined price discount and in-store nutrition education strategy
Number of subjects: 20
Study 21226918 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Number of subjects: 120
Study 21226918 — intervention group
Group type: COMPARATOR
Intervention: Traditional open esophagectomy
Number of subjects: 120
Study 18071677 — intervention group
Group type: EXPERIMENTAL
Intervention: CCKb receptor agonist pentagastrin (0.1 microg/kg)
Number of subjects: 13
Study 18071677 — intervention group
Group type: EXPERIMENTAL
Intervention: mu-opioid receptor agonist remifentanil (0.0625 microg/kg)
Number of subjects: 13
Study 18071677 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study 16826100 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated (HA) ProxiLock femoral hip prostheses
Number of subjects: 42
Study 16826100 — intervention group
Group type: COMPARATOR
Intervention: Titanium (Ti) ProxiLock femoral hip prostheses
Number of subjects: 42
Study 14587169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 0
Study 14587169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 0
Study 14587169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 14587169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0
Study 14587169 — intervention group
Group type: COMPARATOR
Intervention: Oral glycoprotein IIb/IIIa receptor antagonists
Number of subjects: 0
Study 14587169 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 15239621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (target trough level 10-15 ng/mL)
Number of subjects: 77
Study 15239621 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (target trough level not specified)
Number of subjects: 77
Study 15239621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (first phase)
Number of subjects: 77
Study 15239621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (second phase, after excluding obese recipients)
Number of subjects: 77
Study 10510985 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 4736
Study 10510985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 8573755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified care (IC) - hypertension teaching and treatment program based on blood pressure self-monitoring
Number of subjects: 100
Study 8573755 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC) - routine antihypertensive therapy
Number of subjects: 100
Study 2232966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemo-immunotherapy with thymopentin
Number of subjects: 115
Study 2232966 — intervention group
Group type: COMPARATOR
Intervention: Only chemotherapy
Number of subjects: 115
Study 326097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (1.5 g thrice daily for 4 weeks)
Number of subjects: 227
Study 326097 — intervention group
Group type: COMPARATOR
Intervention: Inositol niacinate (1.2 g thrice daily for 4 weeks)
Number of subjects: 227
Study 326097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (1.5 g thrice daily for 6 weeks)
Number of subjects: 227
Study 326097 — intervention group
Group type: COMPARATOR
Intervention: Inositol niacinate (1.2 g thrice daily for 6 weeks)
Number of subjects: 227
Study 31944823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb below the reference range
Number of subjects: 302
Study 31944823 — intervention group
Group type: COMPARATOR
Intervention: Hb within the range
Number of subjects: 302
Study 30861296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresponse system
Number of subjects: 4
Study 27483393 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3811321 (chromosome 14)
Number of subjects: 1638
Study 27483393 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6565887 (chromosome 18)
Number of subjects: 1638
Study 27483393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable adjustments for rs3811321 and rs6565887
Number of subjects: 1638
Study 25997115 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04958242 (0.27 mg)
Number of subjects: 0
Study 25997115 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04958242 (0.35 mg)
Number of subjects: 0
Study 25997115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23514433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + methotrexate
Number of subjects: 31
Study 23514433 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 31
Study 21781980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Calorie Restriction (FCR)
Number of subjects: 25
Study 21781980 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 19619766 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus MVR
Number of subjects: 102
Study 19619766 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 102
Study 17556694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D2/d
Number of subjects: 178
Study 17556694 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D2/mo
Number of subjects: 178
Study 17556694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 178
Study 15453968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 32
Study 15453968 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 11432886 — intervention group
Group type: EXPERIMENTAL
Intervention: IV IL‐2 (18.0 MU/m(2))
Number of subjects: 81
Study 11432886 — intervention group
Group type: EXPERIMENTAL
Intervention: SC IL‐2 (5.0 mU/m(2))
Number of subjects: 81
Study 9738515 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120
Study 9738515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7527107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg/day
Number of subjects: 205
Study 7527107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 205
Study 7527107 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trandolapril 2 mg/day and HCTZ 25 mg/day
Number of subjects: 205
Study 2501093 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN patch (7.5 mg GTN (24h)‐1)
Number of subjects: 40
Study 31533554 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion stigma
Number of subjects: 1207
Study 31533554 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use stigma
Number of subjects: 1207
Study 27511058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified PSt/PK (80:20) fat blend (50g)
Number of subjects: 12
Study 27511058 — intervention group
Group type: COMPARATOR
Intervention: Non-interesterified PSt/PK fat blend (50g)
Number of subjects: 12
Study 27511058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals (IE and non-IE)
Number of subjects: 12
Study 25876297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 300
Study 25876297 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 23338815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (40 min/school day of physical education)
Number of subjects: 446
Study 23338815 — intervention group
Group type: COMPARATOR
Intervention: Control (60 min/week of physical education)
Number of subjects: 446
Study 23338815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 446
Study 21290201 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 60
Study 21290201 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study 19199105 — intervention group
Group type: COMPARATOR
Intervention: Standard decongestive lymphatic therapy (DLT) with pneumatic compression (PC) (bandage group, N = 21)
Number of subjects: 41
Study 19199105 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DLT with Kinesio tape (K-tape) and pneumatic compression (PC) (K-tape group, N = 20)
Number of subjects: 41
Study 17045674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorin Freedom prosthesis
Number of subjects: 80
Study 17045674 — intervention group
Group type: COMPARATOR
Intervention: Carpentier-Edwards Perimount prosthesis
Number of subjects: 80
Study 15530259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd 103 brachytherapy with 90 Gy plus 44 Gy supplemental beam radiation
Number of subjects: 152
Study 15530259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd 103 brachytherapy with 115 Gy plus 20 Gy supplemental beam radiation
Number of subjects: 152
Study 15530259 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Gleason pattern 5 cancer
Number of subjects: 152
Study 15530259 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with biochemical failure
Number of subjects: 152
Study 11573598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 25
Study 11573598 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 25
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent headache (overall prevalence)
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent headache in Caucasians
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent headache by education level
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent headache with migrainous features
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclassified frequent headache
Number of subjects: 13343
Study 15613165 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine criteria
Number of subjects: 13343
Study 7871360 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole 55 mg/g denture lacquer applied once on the mucosal denture surface
Number of subjects: 0
Study 7871360 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 2% gel applied four times daily for 2 weeks
Number of subjects: 0
Study 2904394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 9
Study 2904394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 9
Study 2904394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 9
Study 2904394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31072195 — intervention group
Group type: EXPERIMENTAL
Intervention: L-shaped silicone prosthesis (group A)
Number of subjects: 200
Study 31072195 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PTFE graft (group B)
Number of subjects: 200
Study 31072195 — intervention group
Group type: EXPERIMENTAL
Intervention: silicone graft using the modified double 'V' method (group C)
Number of subjects: 200
Study 31072195 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PTFE graft using the modified double 'V' method (group D)
Number of subjects: 200
Study 31072195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 200
Study 31233260 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training
Number of subjects: 0
Study 31233260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0